MYGN at a glance
MYRIAD GENETICS INC (MYGN, SEC CIK 899923) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MYRIAD GENETICS INC (MYGN) reported revenue of $824.5 million (down 1.6% from FY2024) and a net loss of $365.9 million. Diluted EPS was -$3.95.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding MYRIAD GENETICS INC (MYGN) shares worth $234.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Davis Mark Steven on November 18, 2026 of 6,100 shares at $5.62 per share.
- In the last 90 days, MYGN insiders reported 0 open-market purchases ($0) and 1 open-market sale ($34K) on Form 4, a net sale of $34K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $824.5M
- −1.6% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$34K
- 13F holders
- 26 funds
- $234.5M · −1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $202.7M, down $3.0M YoY from $205.7M
- Cost-of-revenue margin 67.9% vs 69.9% YoY, with cost of revenue 32.1% vs 30.1%
- Best segment Mental Health, revenue $39.5M vs $38.7M; worst Prenatal Health, $39.3M vs $44.5M
- Cash $107.1M vs $149.6M at December 31, 2025, with operating cash use of $30.5M
- Prenatal Health sale for $210M plus inventory, expected closing early 2027; reimbursement pressure and coverage limitations remain headwinds
Risk Factors
- Newly added transaction risk: Prenatal Health sale to Laboratory Corporation of America for $210 million plus inventory remains subject to regulatory approvals
- Regulatory risk: Hart-Scott-Rodino and state healthcare clearances could delay, condition, or block closing
- Operational risk: Sale restrictions may limit Prenatal Business responses to market developments before closing
- Financial risk: Lower post-sale revenue base increases risk of breaching the Credit Agreement revenue covenant
- Liability risk: Myriad retains certain Prenatal billing, coding, reimbursement liabilities and indemnification obligations
AI summary of the MYGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- One-time retention options target executive continuity during operational-efficiency and financial-performance initiatives
- CFO Benjamin Wheeler awarded options for 121,379 shares
Item 8.01: Other Events
- Unauthorized network access detected November 2, 2026, creating cybersecurity, privacy and operational risks
- Testing operations and order management systems temporarily suspended during containment and investigation
Item 2.02: Results of Operations and Financial Condition
- Myriad Genetics announced financial results for the three months ended September 30, 2026
- Detailed results and management commentary appear in Exhibit 99.1, the attached earnings release
Item EX-99.1: Item EX-99.1
- Q3 revenue $202.7M, down 1% YoY, while average revenue per test rose 1% as payer and revenue-cycle initiatives gained traction
- Core Cancer Care Continuum and Mental Health volume increased 3% YoY to 239,000 tests, offset by Prenatal volume declining 11%
AI summaries of MYGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MYGN
Don't miss the next MYGN filing
- Alerts as it files. A push when MYGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MYGN, by share count.
- Ask anything. An AI agent that reads every MYGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Davis Mark Steven | Sell | Nov 18, 2026 | 6,100 | $5.62 |
| Muzzey Dale | A | Nov 6, 2026 | 92,632 | - |
| Sikri Vishal | A | Nov 6, 2026 | 53,236 | - |
| Fox Jennifer Lynne | A | Nov 6, 2026 | 139,267 | - |
| Jampa Raj | A | Nov 6, 2026 | 58,560 | - |
| Wheeler Benjamin Richard | A | Nov 6, 2026 | 121,379 | - |
| Solaiman Shereen | A | Nov 6, 2026 | 83,049 | - |
| Verratti Mark | A | Nov 6, 2026 | 146,933 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $837.6M | $824.5M |
| Gross Profit | $517.0M | $585.4M | $576.6M |
| Operating Income | - | -$123.5M | -$387.2M |
| Net Income | -$263.3M | -$127.3M | -$365.9M |
| Gross Margin | - | 69.9% | 69.9% |
| Op. Margin | - | -14.7% | -47.0% |
| Net Margin | - | -15.2% | -44.4% |
| Balance Sheet | |||
| Total Assets | $1.1B | $1.0B | $706.6M |
| Equity | - | $701.1M | $368.0M |
| ROE | - | -18.2% | -99.4% |
| Per Share | |||
| EPS | - | $-1.41 | $-3.95 |
| Cash Flow | |||
| Operating CF | -$110.9M | -$8.7M | $1.8M |
Source: XBRL data in MYRIAD GENETICS INC (MYGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MYGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $234.5M |
| Q2 2026 | 27 | $290.0M |
| Q1 2026 | 28 | $205.7M |
| Q4 2025 | 27 | $349.4M |
| Q3 2025 | 28 | $387.4M |
| Q2 2025 | 29 | $295.8M |
| Q1 2025 | 26 | $315.3M |
| Q4 2024 | 21 | $414.8M |
- BlackRock+5.03M (+46%)
- Ameriprise Financial+1.62M (+621%)
- Citadel Advisors LLC+618.9K (+40%)
- Millennium Management+608.9K (+9%)
- D.E. Shaw & Co+104.7K (+2%)
- AQR Capital Management−1.50M (-54%)
- Morgan Stanley−579.8K (-23%)
- Bank of America Corp−313.3K (-35%)
- Dimensional Fund Advisors−267.6K (-25%)
- Prudential Financial−265.7K (-43%)
- Renaissance Technologies LLC+243.6K
- FMR LLC (Fidelity)−772.2K
- Fifth Third Bancorp−256
Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MYGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Oct 20, 2026 | - | Analysis | - |
| 8-K | Oct 9, 2026 | - | Analysis | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| SC 13G | Sep 4, 2026 | - | - | |
| 4 | Aug 17, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
Related Health Care companies
- TKNO · Alpha Teknova, Inc.In Vitro & In Vivo Diagnostic Substances
- CLDX · Celldex Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- NTLA · Intellia Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- LNTH · Lantheus Holdings, Inc.In Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- QDEL · QuidelOrtho CorpIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
MYGN SEC filings: frequently asked questions
Are MYGN insiders buying or selling?
In the last 90 days, MYRIAD GENETICS INC (MYGN) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $34,252 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MYGN stock?
As of September 30, 2026, the largest MYRIAD GENETICS INC (MYGN) holders among the 13F filers tracked by SignalX were BlackRock ($68.6 million), Millennium Management ($31.2 million), State Street Corp ($20.7 million), D.E. Shaw & Co ($20.2 million), Vanguard Capital Management LLC ($17.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MYGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MYRIAD GENETICS INC (MYGN) reported revenue of $824.5 million (down 1.6% from FY2024) and a net loss of $365.9 million. Diluted EPS was -$3.95. The figures come from the XBRL data in the 10-K.
What did MYGN report in its latest 8-K?
MYRIAD GENETICS INC (MYGN) filed an 8-K on November 9, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). One-time retention options target executive continuity during operational-efficiency and financial-performance initiatives.
What are the latest MYGN SEC filings?
MYRIAD GENETICS INC (MYGN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 19, 2026.
What is MYGN's SEC CIK number?
MYRIAD GENETICS INC (MYGN)'s SEC Central Index Key (CIK) is 899923. EDGAR lists every MYGN filing under that number.
Ask anything about MYGN
The research agent reads MYGN's filings, financials, insider trades and 13F holders, then answers with sources.